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Abstract
Background: The identification of oncogenic driver mutations has largely relied on the assumption that genes that
exhibit more mutations than expected by chance are more likely to play an active role in tumorigenesis. Major cancer
sequencing initiatives have therefore focused on recurrent mutations that are more likely to be drivers. However, in
specific genetic contexts, low frequency mutations may also be capable of participating in oncogenic processes.
Reliable strategies for identifying these rare or even patient-specific (private) mutations are needed in order to
elucidate more personalized approaches to cancer diagnosis and treatment.
Methods: Here we performed whole-exome sequencing on three cases of childhood pre-B acute lymphoblastic
leukemia (cALL), representing three cytogenetically-defined subgroups (high hyperdiploid, t(12;21) translocation, and
cytogenetically normal). We applied a data reduction strategy to identify both common and rare/private somatic
events with high functional potential. Top-ranked candidate mutations were subsequently validated at high
sequencing depth on an independent platform and in vitro expression assays were performed to evaluate the
impact of identified mutations on cell growth and survival.
Results: We identified 6 putatively damaging non-synonymous somatic mutations among the three cALL
patients. Three of these mutations were well-characterized common cALL mutations involved in constitutive
activation of the mitogen-activated protein kinase pathway (FLT3 p.D835Y, NRAS p.G13D, BRAF p.G466A). The
remaining three patient-specific mutations (ACD p.G223V, DOT1L p.V114F, HCFC1 p.Y103H) were novel mutations
previously undescribed in public cancer databases. Cytotoxicity assays demonstrated a protective effect of the ACD
p.G223V mutation against apoptosis in leukemia cells. ACD plays a key role in protecting telomeres and recruiting
telomerase. Using a telomere restriction fragment assay, we also showed that this novel mutation in ACD leads to
increased telomere length in leukemia cells.
Conclusion: This study identified ACD as a novel gene involved in cALL and points to a functional role for ACD in
enhancing leukemia cell survival. These results highlight the importance of rare/private somatic mutations in
understanding cALL etiology, even within well-characterized molecular subgroups.
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Background
Childhood acute lymphoblastic leukemia is a hetero-
geneous disease both biologically and clinically, and is
the leading cause of cancer-related deaths among chil-
dren. Despite significant advances in our understand-
ing of the pathobiology of cALL leading to risk-based
treatment regimens and increased survival rates, the
etiological causes of this disease remain elusive. Ap-
proximately 75 % of pre-B cALL cases exhibit hyperdiploidy
or a recurring gross chromosomal rearrangement, detection
of which is central to disease diagnosis, risk stratification
and management [1]. While these chromosomal alterations
play an important role in driving the leukemic process by af-
fecting molecular pathways that halt lymphoid progenitor
cell differentiation and promote cell proliferation and sur-
vival, they are not sufficient for leukemic transformation and
are often detected years before leukemia onset. This suggests
a need for additional cooperating events in order to achieve
overt leukemogenesis [2]. Thorough investigation of cALL
genomes is crucial to better understand the underlying gen-
omic complexity of this disease and thus better diagnose
and treat it. Toward these goals, recent large-scale sequen-
cing efforts revealed many somatic driver mutations/genes
recurrently mutated in cALL [1]. The identification of these
high frequency driver mutations is essential to better under-
stand disease etiology and characterize prognostic sub-
groups. Yet accumulating evidence has also shown that low-
frequency mutations within a cancer type can contribute to
onset and progression of the disease [3], and play a role in
intra-tumor and inter-patient heterogeneity. The identifica-
tion of patient-specific mutations could provide crucial in-
formation regarding molecular pathways underlying cALL
tumorigenesis and thus point to new therapeutic avenues.
Here, we performed whole-exome sequencing of 3 pre-B
cALL cases. Case 1 was diagnosed with high hyperdiploiy
(>50 chromosome) cALL and Case 2 harboured the t(12;21)
(ETV6-RUNX1) translocation. Together these two molecu-
larly defined subgroups represent over 40 % of cALL cases.
Case 3 was cytogenetically normal at diagnosis. Using a
unique quartet design, we sequenced matched normal
(blood following remission) and tumor (bone marrow at
diagnosis) patient samples, and the parents of each case. We
successfully identified known recurrent drivers, as well as
novel patient-specific somatic mutations with high func-
tional potential. Using in vitro assays, we showed that the
private p.G223V mutation, adjacent to the TEL patch of the
telomere protein ACD (also known as TPP1), leads to apop-
tosis resistance and may contribute to leukemia cell survival
by promoting telomere maintenance and protection.
Methods
Patients
All study subjects were self-declared French-Canadians
of European descent from the established Quebec cALL
(QcALL) cohort [4]. The Sainte-Justine UHC Research
Ethics Board approved the protocol. Informed consent
was obtained from the parents of the patients to partici-
pate in this study and for publication of this report and
any accompanying images. A copy of the written consent
is available for review by the Editor of this journal.
Case 1, a 10 year old male, was classified as high risk
based on his age. He presented with a platelet count of
15.0 × 109/L, a white blood cell count (WBC) of 9.0 ×
109/L, and 63 % and 97 % lymphoblast cells in the blood
and bone marrow samples respectively. The cytogen-
etic analysis revealed high hyperdiploidy (karyotype:
53,XY,+3,+4,+6,+10,+14,+17,+18). He was enrolled on
the Dana Farber Cancer Institute (DFCI) ALL Consortium
protocol 95–01. He achieved complete remission and has
been out of treatment for over 60 months with leukemia
free-survival (LFS).
Case 2 was a 4 year old female with a platelet count of
35.0 × 109/L, a WBC of 33.1 × 109/L, and 75 % and 96 %
lymphoblast cells in the blood and bone marrow samples
respectively. Cytogenetic analysis revealed a t(12;21) trans-
location. Despite her karyotype, usually associated with a
good prognostic, she was classified as high risk based on
the presence of leukemia cells in the cerebrospinal fluid.
She was enrolled on DFCI/ALL Consortium protocol
2000–01. She also achieved complete remission and has
been out of treatment for over 60 months with LFS.
Case 3 was a 6 year-old male with a WBC of 183.1 ×
109/L, a platelet count of 29.0 × 109/L, 87 % and 95 %
lymphoblast cells in the blood and bone marrow samples
respectively, and presented with a normal karyotype ac-
cording to the cytogenetic analysis. The patient was classi-
fied as high risk based on hyperleukocytosis and was
treated on DFCI/ALL Consortium Protocol 2000–01. Case
3 experienced a first relapse 41 months post diagnosis, and
following 2 subsequent relapses he died 73 months post
diagnosis.
Whole exome sequence capture and sequencing
DNA was extracted from bone marrow samples (at diag-
nosis) and peripheral blood samples (obtained after remis-
sion) from the cases and their parents using standard
protocols as described previously [5]. Whole exomes were
captured in solution with Agilent’s SureSelect Human All
Exon 50 Mb kits for SOLiD sequencing (Life Technolo-
gies) according to the manufacturer’s protocol, were se-
quenced on the Life Technologies SOLiD System (mean
coverage =32X) and aligned to the Hg19 reference gen-
ome using LifeScope Genomic Analysis Software (see
Fig. 1 for complete sequencing analysis workflow). Poly-
merase chain reaction (PCR) duplicates were removed
using Picard [http://broadinstitute.github.io/picard/]. Base
quality score recalibration was performed using the
Genome Analysis ToolKit (GATK) [6] and reads that
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failed the quality control were removed. Cleaned BAM
files were used to create pileup files using SAMtools [7].
Somatic single nucleotide variants (SNVs) were called
from pileup files using SNooPer, an in-house variant caller
that is based on a machine learning approach that inte-
grates tumoral and normal data and that was specifically
trained for optimal identification of somatic mutations in
our low-depth SOLiD sequencing data (manuscript sub-
mitted and software available upon request). Furthermore,
using the familial design, we were able to use parental se-
quence information to remove Mendelian inconsistencies,
reduce false-positive sequencing and alignment errors and
facilitate somatic variant identification. The robustness of
this approach was further demonstrated using high-depth
sequencing on an independent platform to confirm top-
ranked somatic mutations (see below). Resulting somatic
SNVs were queried against publically available datasets
such as 1000 Genomes [8] and NHLBI GO Exome Sequen-
cing Project (ESP) [http://evs.gs.washington.edu/EVS/] to
filter out common polymorphism eventually remaining
(minor allele frequency >0.01).
Expression data filter
Publically available microarray expression data [9] were
used to filter variants based on the assumption that
expressed genes are more likely to carry functionally rele-
vant mutations [10]. Mutated genes identified from each
case were compared to the expression profiles of the cor-
responding cALL subgroup (hyperdiploidy, t(12;21), or
“others”) and only expressed genes were subsequently
retained in the somatic variant analysis.
Ultra-deep targeted re-sequencing
Top-ranked rare/private candidate mutations, as well as
common somatic mutations identified in the pre-B cALL
cases were validated on the Ion Torrent system. Selected
variant regions (~125pb flanking the identified somatic
mutation) were amplified and PCR products were se-
quenced on the Ion PGM Sequencer (Life Technologies)
according to the manufacturer’s protocol with a mean
coverage >1,800X. Primer sequences and PCR protocols
are available upon request.
Fig. 1 Whole-exome sequencing analysis workflow. Boxes represent
the analysis/cleaning steps. Cylinders represent the SNV filtering steps
used in the data reduction strategy to identify functional
somatic mutations. The number of variations remaining after each step
is shown in brackets. Note that only SNVs that passed a given filter
were tested for in the subsequent step. Using public databases and
variant annotation tools, we identified 6 top-ranked mutations among
the pre-B cALL patients, including 3 SNVs referenced in COSMIC v71
and 3 candidate rare/private SNVs in ACD (p.G223V), DOT1L (p.V114F)
and HCFC1 (p.Y103H) with a potential functional impact
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Site-directed mutagenesis and apoptosis assay
Identified mutations were introduced by site-directed
mutagenesis into the complementary DNA (cDNA) se-
quence of each gene cloned into a pDONR221 vector.
Using the pLenti-CMV-DEST Gateway Vector (w118-1),
we subcloned the wild-type (WT) or mutant coding se-
quences and generated lentiviruses using a Third Gener-
ation Packaging System in 293 T cells. Lentiviral particles
were then harvested and used to infect Nalm-6 (human
leukemia pre-B cells) with 8ug/mL polybrene. Infected
cells were selected with puromycin 1 μg/μL, seeded at
5 × 105 cells/mL in their culture medium and treated with
5 μM of camptothecin for 3 h. Apoptosis was measured
using conventional Annexin V/Propidium iodide (PI)
staining and quantified by flow cytometry (BD Biosciences
FACS Fortessa). All experiments were done in triplicate.
Telomere restriction fragment (TRF) assay
Parental Nalm-6 cells and Nalm-6 cells overexpressing
mutant ACD p.G223V (Nalm-6 ACD G223V), the wild-
type ACD (Nalm-6 ACD WT) or Nalm-6 cells infected
with the empty vector alone (Nalm-6 pLENTI) were used
for TRF assays. For each cell line, extracted DNA at pas-
sage 16 (p16) (population doublings ≈ 50) and p27 (popula-
tion doublings ≈ 80) after selection was digested with HinfI
and RsaI restriction enzymes and fractionated on an
electrophoresis gel apparatus. After drying, the gel was hy-
bridized with a [γ -32P] adenosine triphosphate (ATP)end-
labelled (T2AG3)3 probe and exposed on X-ray film. Mean
TRF length was calculated as previously described [11].
The TRF assay was performed in duplicate.
Results/discussion
Assuming that functionally important genes can also be
mutated more rarely and in specific tumor contexts, we
performed whole-exome sequencing of three pre-B cALL
patients and their parents and applied a data reduction
strategy to identify both common and novel rare/private
events with high functional potential (Fig. 1). SNVs were
queried against public databases, annotated using ANNO-
VAR [12], and were binned according to frequency and
function (Methods). Non-synonymous mutations that were
expressed in cALL subgroups (based on microarray cALL
expression data [9]) were then filtered based on a CONsen-
sus DELeteriousness score >0.6 (measure of the degree of
coherence of individual methods about the likelihood that
a SNV is deleterious) [13]. This led to the identification of
6 expressed damaging non-synonymous somatic mu-
tations among the 3 patients (FLT3 p.D835Y, NRAS
p.G13D, BRAF p.G466A, ACD p.G223V, DOT1L p.V114F,
HCFC1 p.Y103H) (Table 1) that were subsequently con-
firmed using targeted ultra-deep re-sequencing (mean
coverage >1800X). Among these 6 somatic SNVs, FLT3
p.D835Y, NRAS p.G13D and BRAF p.G466A were
referenced in the Catalogue Of Somatic Mutations In Can-
cer (COSMIC) database (v71) and previously shown to
constitutively activate the mitogen-activated protein kinase
(MAPK) pathway and to increase tumor proliferation
[14–17]. The identification of previously reported driver
mutations validates the robustness of our approach. The
NRAS p.G13D gain of function mutation was identified in
Case 1, which corroborates previous studies that report
postnatal RAS activating mutations in ~30 % of pre-B
hyperdiploid cALL patients [18]. The BRAF p.G466A mu-
tation identified in Case 2 is associated with a mild in-
crease of ERK activation [19]. While mutations in BRAF
are identified in almost 70 % of patients with multiple
myeloma [15], screening of childhood pre-B cohorts only
identified a few cases harbouring these events [20]. Al-
though alterations of the receptor tyrosine kinase FLT3
are frequent in hyperdiploid cALL and rare in other sub-
types [21], FLT3 p.D835Y was identified in the cytogeneti-
cally normal Case 3. While Case 3 suffered a relapse and
activated forms of FLT3 are usually associated with a poor
outcome in acute myeloid leukemia patients [22], this as-
sociation is not confirmed in cALL [23].
Our sequencing analysis pipeline also led to the identi-
fication of three candidate novel pathogenic mutations
in Cases 1 and 2 (DOT1L p.V114F, HCFC1 p.Y103H,
ACD p.G223V), that were neither previously reported nor
referenced in public databases. Based on our strict filtering
criteria, no private mutations were identified in Case 3.
DOT1L is a histone writer and HCFC1 is a broad tran-
scription regulator that plays a critical role in cell prolifer-
ation via its involvement in chromatin-modifying activities
[24]. These results are consistent with recent cancer se-
quencing initiatives that highlighted the important role of
chromatin remodeling genes in leukemogenesis [25]. Fur-
thermore, DOT1L has recently been implicated in the de-
velopment of MLL-rearranged leukemia and shown to be
essential for leukemic transformation [26]. On the other
hand, ACD is a core protein in the shelterin complex and
mediates the access of telomerase to the telomere. It is es-
sential for telomere homeostasis in hematopoietic stem
and progenitor cell particularly [27, 28].
The high variant allele frequency (VAF) of these rare/pri-
vate mutations (DOT1L, VAF =0.46; HCFC1, VAF =0.51;
ACD, VAF =0.51), calculated based on our ultra-deep tar-
geted re-sequencing data (Table 1), was indicative of early
clonal selection supporting a possible functional role in
leukemia development. Functional validation of the ACD
p.G223V mutation (Fig. 2a) was further pursued using in
vitro expression assays, however our in vitro lentiviral ex-
pression system did not permit functional characterization
of neither DOT1L nor HCFC1, due to the size of the open
reading frames (ORFs) (4.6 kb and 6.1 kb, respectively) that
were beyond the viral packaging capacity of the capside
[29]. Further investigation of these two novel mutations
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using alternative functional screening methods is ongoing.
In vitro expression assays of ACD using the topoisomerase
I inhibitor camptothecin, showed that leukemic cells over-
expressing mutant p.G223V ACD (Nalm-6 ACD G223V)
exhibit lower levels of apoptosis compared with cells over-
expressing wild-type ACD (Nalm-6 ACD WT) (P =0.014,
Mann–Whitney U test) and the empty vector (Nalm-6
pLenti) (P =0.014, Mann–Whitney U test) (Fig. 2b). The
p.G223V mutation is adjacent to the TEL patch in the
oligonucleotide/oligosaccharide-binding (OB) fold domain
of ACD that interacts directly with the catalytic sub-
unit of telomerase. Within the shelterin complex, ACD
was specifically shown to interact with POT1 to protect
telomeres and recruit telomerase at chromosome ends
Table 1 Candidate somatic mutations identified in each patient
Patient Subgroup Gene Genomic change Protein change Class VAF COSMIC v71
Case 1 HD NRAS g.chr1:115258744C > T p.G13D Missense 0.48 Haematopoietic and Lymphoid tissue
ACD/TPP1 g.chr16:67693443C > A p.G223V Missense 0.51 -
DOT1L g.chr19:2191086G > T p.V114F Missense 0.46 -
Case 2 t(12;21) BRAF g.chr7:140481411C > G p.G466A Missense 0.15 Thyroid
HCFC1 g.chrX:153230064A > G p.Y103H Missense 0.51 -
Case 3 CN FLT3 g.chr13:28592642G > T p.D835Y Missense 0.44 Haematopoietic and Lymphoid tissue
Variant allele frequencies (VAF) (number of supporting reads/coverage) were calculated based on ultra-deep targeted re-sequencing data (mean coverage >1800X).
Only tissue types harbouring the highest occurrence of the mutation in the COSMIC database (v71) are presented. HD hyperdiploid, CN Cytogenetically normal
Fig. 2 ACD p.G223V protects from camptothecin-induced apoptosis and increases telomere length. a. Schematic representation of the ACD protein.
The p.G223V mutation, depicted in black, is adjacent to the TEL patch of the OB-fold domain involved in telomerase recruitment and composed of
seven critical amino acids located in a region defined by the curly bracket (E168, E169, E171, R180, L183, L212 and E215) [30]. p.Q320X, p.P491T and
p.K170del, depicted in grey, are three germline mutations recently identified and associated with familial melanomas and bone marrow
failure disorders [34–36]. TPP1C corresponds to the TIN2-binding domain. Together, the OB (oligonucleotide/oligosaccharide-binding) and
PBD (POT1 binding domain) domains form the ACDN domain necessary for POT1 binding to telomeric DNA and the stimulation of telomerase processivity.
b. In vitro apoptosis assays show overall reduced levels of apoptosis associated with ACD p.G223V. The c.659 g > t mutation was introduced into the ACD
transgene by site-directed mutagenesis and expressed in Nalm-6 cells. The graph shows annexin V/PI staining for 3 h on Nalm-6 pLenti (empty vector),
Nalm-6 ACD WT and Nalm-6 ACD G223V cells. c. The telomere restriction fragment assay (TRF) showed a quantitative increase in telomere size for Nalm-6
ACD G223V cells at passage 16 (p16) and p27 after selection. Mean TRF length = ∑ (ODi)/∑ (ODi/Li) where ODi is the radioactive signal, Li
is the TRF fragment length at position i. The bar chart of Fig. 2c (bottom) represents the mean TRF length for each condition directly
quantified from each corresponding lane of the TRF gel presented at the top of Fig. 2c Significance (in b and c) was determined by a
Mann–Whitney U test; p-values <0.05 are represented by an asterisk
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[30–32]. Interestingly, recurrent somatic mutations in the
OB domains of POT1 have been shown to cause telomere
dysfunction in chronic lymphocytic leukemia suggesting
that alteration of shelterin-mediated protein-telomere
binding could lead to genomic instability and cancer [33].
Furthermore, very recently, germline mutations in the
POT1 binding domain and the TEL patch of ACD were
respectively associated with familial melanomas and bone
marrow failure disorders [34–36] (Fig. 2a). Although fur-
ther studies are needed to decipher the underlying mo-
lecular mechanisms implicating ACD in apoptosis
inhibition, taken together, these data strongly support
a role for ACD p.G223V in promoting leukemia cell
maintenance.
To further investigate the effect of p.G223V mutant
ACD on telomere structure, we performed a TRF assay
(Fig. 2c) and showed that decreased apoptosis correlates
with increased telomere length in Nalm-6 ACD G223V
at both tested passages compared to Nalm-6 ACD WTand
Nalm-6 pLenti (P =0.029, Mann–Whitney U test), con-
firming stable alteration of telomere homeostasis. ACD
mutant induced telomere elongation in leukemia cells is
consistent with reports demonstrating disrupted shelterin
complex function and telomere lengthening due to muta-
tions in POT1 in chronic lymphocytic leukemia [33, 37].
Furthermore, as observed for POT1 at the same population
doubling point [33], overexpression of WT ACD did not
increase telomere length (Fig. 2c), confirming that the ob-
served telomere lengthening is due to the p.G223V muta-
tion and not caused by global overexpression of ACD.
Concomitant lengthening of the telomeres and decreased
apoptosis levels in NALM-6 ACD G223V following camp-
tothecin treatment corroborates previous findings that al-
tered telomerase activity can lead to hypersensitivity of
tumor cells to topoisomerase inhibitors [38, 39]. Further
investigation is required to characterize the influence of the
p.G223V mutation on the recruitment and processivity of
telomerase and on telomere-length regulation. Missense or
frameshift mutations in ACD, many of which are located in
the OB fold, adjacent to the TEL patch, and in the POT1
interaction domain, have been described in multiple cancer
types (Additional file 1 Table S1) with the highest preva-
lence found in melanoma (2.7 %), suggesting that ACD
mutations may participate in a common underlying
cancer-promoting pathway that involves telomere dysfunc-
tion. Case 1 who carries the ACD p.G223V mutation had
high hyperdiploid cALL and although telomere dysfunction
can cause chromosome destabilization and aneuploidy
[40, 41], it is unlikely that this mutation precluded the mi-
totic event producing the hyperdiploid phenotype. How-
ever, our results do support a role for ACD p.G223V in
the earlier stages of clonal expansion contributing to telo-
mere maintenance and apoptosis resistance, at least in
vitro. Further investigation is required in order to
characterize the mechanistic role of ACD p.G223V within
this patient’s specific tumor context.
Conclusions
The prenatal origins of cALLs are well established, along
with the need for additional postnatal mutations in order
to drive overt leukemogenesis [42, 43]. The extent to
which rare/private genetic events contribute to the onset
and progression of cALL however is largely unknown.
Through whole-exome sequencing of 3 cALL cases, we
successfully identified not only common drivers (NRAS
p.G13D, FLT3 p.D835Y, and BRAF p.G466A), but also
rare/private somatic mutations (DOT1L p.V114F, HCFC1
p.Y103H, ACD p.G223V), in well-characterized cALL mo-
lecular subgroups. The identification of patient-specific
events with a functional potential is not surprising and fur-
ther confirms the underlying genetic complexity of this dis-
ease. We went on to demonstrate the functional impact of
ACD p.G223V on apoptosis resistance and telomere-
length regulation in pre-B ALL cells. The high VAF of
this somatic mutation suggests that it is likely present in
the major subclone; while this does not necessarily imply
functionality, it does support an early role for ACD
p.G223V in driving the leukemic process. Though fur-
ther investigation is needed to fully characterize the influ-
ence of the identified mutation on telomere homeostasis,
this study is the first to describe the functional implications
of a somatic mutation in ACD on leukemic cell behaviour,
supporting a role for ACD and telomere regulation in
leukemia cell resistance to apoptosis. In conclusion, these
results support the need of thorough investigation of rare/
private mutations to reveal the underlying complexity of
cALL landscapes, including within well-characterized sub-
groups, and the inter-patient variability that may influence
diagnosis and prognosis.
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